AstraZeneca is planning filings of its chronic obstructive pulmonary disease drug Bevespi Aerosphere in China and Japan, based on a new set of positive phase 3 trial results.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
